SCHEMBL5437224

SCHEMBL5437224

COc1ccc2c(c1)c(C)cc(=O)n2Cc1ccc(Cl)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.60
TSHR P16473 3/20 0.60
MEN1 O00255 2/20 0.60
MAPK1 P28482 2/20 0.60
LMNA P02545 2/20 0.60
CYP1A2 P05177 2/20 0.60
CYP3A4 P08684 2/20 0.60
CYP2C9 P11712 2/20 0.60
CYP2C19 P33261 2/20 0.60
PMP22 Q01453 2/20 0.60
RGS12 O14924 1/20 0.60
ALDH1A1 P00352 1/20 0.60
MAPT P10636 1/20 0.60
PKM P14618 1/20 0.60
NFKB1 P19838 1/20 0.60
GNAI1 P63096 1/20 0.60
HIF1A Q16665 1/20 0.60
PTGS2 P35354 4/20 0.56
PTGS1 P23219 1/20 0.56
PLA2G2A P14555 3/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12301941 0.88 KMT2A (0.68) KMT2ATSHRMEN1MAPK1PLA2G2A
SCHEMBL11460374 0.86 MEN1 (0.60) KMT2ATSHRMEN1MAPK1LMNA
SCHEMBL11461389 0.81 PLA2G2A (0.58) KMT2ATSHRMEN1MAPK1LMNA
SCHEMBL10627225 0.80 MAPT (0.67) KMT2ATSHRMEN1MAPK1LMNA
SCHEMBL5444674 0.80 MEN1 (0.81) KMT2AMEN1MAPK1LMNACYP1A2
SCHEMBL9959549 0.80 LMNA (0.73) KMT2ATSHRMEN1MAPK1LMNA
SCHEMBL11460501 0.79 USP14 (0.50) KMT2AMEN1LMNACYP1A2CYP2C9
SCHEMBL3471153 0.78 KMT2A (0.68) KMT2ATSHRMEN1MAPK1PLA2G2A
SCHEMBL2800952 0.77 PTGER4 (0.52) KMT2ATSHRMEN1MAPK1LMNA
SCHEMBL9736453 0.76 MAPT (0.58) KMT2ATSHRMEN1MAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130109652-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS ADDEX PHARMACEUTICALS S.A. (CH) 2013-05-02 US disclosed
US-8399493-B2 Pyridinone derivatives and their use as positive allosteric modulators of mGluR2-receptors Janssen Pharmaceuticals, Inc. (US) 2013-03-19 US disclosed
US-20070213323-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS Janssen Pharmaceuticals, Inc. 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213323-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS GRM2, GRM1, GRM3 KMT2A 1937/4885TSHR 250/4885MEN1 3509/4885
US-20130109652-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS GRM2, GRM1, GRIA2 KMT2A 1513/4885TSHR 353/4885MEN1 3869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.